Background: Mucormycosis is a rare but critical infection. Due to its rarity, there is scarce evidence about the longitudinal changes in the epidemiology of mucormycosis in the US.Objectives: We investigated the longitudinal epidemiology, detailed clinical characteristics, treatment and outcomes of patients with mucormycosis within the US Veterans Health Administration (VHA) over 20‐year period.Patients/Methods: All adult patients who were admitted to an acute‐care hospital with a diagnosis of mucormycosis within the VHA from January 2003 to December 2022.Results: Our study included 201 patients from 68 hospitals. Incidence rates of mucormycosis increased from 1.9 per 100,000 hospitalisations in 2003 to 3.3 per 100,000 hospitalisations in 2022, with a peak incidence at 5.9 per 100,000 hospitalisations in 2021, when the Delta wave of COVID‐19 hit the US. Rhino‐orbital (37.3%) and pulmonary mucormycosis (36.8%) were the most common types of infection. Diabetes mellitus (59.1%) and leukaemia (28.9%) were most common comorbidities predisposing to mucormycosis. Use of posaconazole or isavuconazole increased over time. The 90‐day and 1‐year mortalities were 35.3% and 49.8%, respectively. The mortality was lower in more recent years (2013–2017, 2018–2022) compared to earlier years (2003–2007). Age ≥65 (adjusted odds ratio [aOR]: 3.47, 95% CI 1.59–7.40), leukaemia as a comorbidity (aOR: 2.66, 95% CI 1.22–5.89) and central nervous system infection (aOR: 10.59, 95% CI 2.81–44.57) were significantly associated with higher 90‐day mortality.Conclusions: Our longitudinal cohort study suggests the increasing incidence rates but lower mortality of mucormycosis over this 20‐year period.
11 November 2024 in Antimicrobial Stewardship & Healthcare Epidemiology
For adult patients with Staphylococcus aureus bacteremia (SAB), Infectious Diseases consultation (IDC) significantly lowers mortality and recurrence rate. Our systematic review and meta-analysis demonstrate that IDC is also associated with significantly lower mortality in children with SAB. Analysis of the impact of IDC on pediatric recurrence rates revealed moderate heterogeneity.
The brown recluse spider (Loxosceles reclusa) is endemic to the southcentral Midwest and the Southern United States. A bite from a brown recluse spider may result in symptoms that range from local skin necrosis to systemic complications such as acute haemolytic anaemia, disseminated intravascular coagulopathy, rhabdomyolysis and death. Although rare, systemic loxoscelism is a clinical diagnosis of exclusion that should be considered in a patient with acute autoimmune haemolytic anaemia. We describe a case of a young man with autoimmune haemolytic anaemia secondary to systemic loxoscelism successfully treated with intravenous immunoglobulin and steroids.
Brodie’s abscess is a subacute or chronic osteomyelitis characterised by an intraosseous abscess. It may present months to years after the inciting event. Staphylococcus aureus is the most common causative organism of Brodie’s abscess, while Gram-negative bacteria are uncommon causative organisms. A combination of culture-directed antibiotics and surgical debridement is key to successful management. This case report describes a patient with a history of minor trauma preceding the development of Brodie’s abscess of the calcaneus caused by Serratia marcescens. This was managed successfully with surgical debridement, followed by oral antibiotics.